AAP
GYRE icon

Ardsley Advisory Partners’s Gyre Therapeutics GYRE Stock Holding History

Ardsley Advisory Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$205K – 154
2017
Q4 		$205K Buy
+2,000
New +$102K 0.02% 126

Other funds holding GYRE

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ardsley Advisory Partners's GYRE Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of Gyre Therapeutics (GYRE) in Q1 2018, closing a stake of 2,000 shares — an estimated $205K sold.

Ardsley Advisory Partners first reported a position in GYRE in Q4 2017 and held it in 1 quarter. The position peaked at $205K in Q4 2017. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2018.

  • Ardsley Advisory Partners reported no remaining Gyre Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ardsley Advisory Partners sold 2,000 Gyre Therapeutics shares in Q1 2018, an estimated $205K.
  • Ardsley Advisory Partners first reported a position in Gyre Therapeutics in Q4 2017 and held it in 1 quarter.
  • Ardsley Advisory Partners's Gyre Therapeutics position peaked at $205K in Q4 2017.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.